SCHEMBL26239757

SCHEMBL26239757

COc1ccccc1CN(CCC(C)C)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.55
ACHE P22303 3/20 0.55
CHRM2 P08172 6/20 0.50
SLC6A2 P23975 2/20 0.49
SLC6A4 P31645 2/20 0.49
AOC3 Q16853 1/20 0.49
MEN1 O00255 1/20 0.43
CRHBP P24387 1/20 0.43
KMT2A Q03164 1/20 0.43
CRHR2 Q13324 1/20 0.43
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
IDO1 P14902 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
CHRM1 P11229 4/20 0.42
CHRM4 P08173 3/20 0.42
CHRM5 P08912 3/20 0.42
CHRM3 P20309 3/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133192 0.84 ACHE (0.55) BCHEACHECHRM2SLC6A2SLC6A4
SCHEMBL23792428 0.79 HTR1A (0.40) BCHEACHEKMT2AIDO1TAAR1
SCHEMBL23792417 0.79 SLC6A2 (0.46) SLC6A2SLC6A4AOC3HPGDIDO1
SCHEMBL22340428 0.77 SLC6A2 (0.47) BCHEACHECHRM2SLC6A2SLC6A4
SCHEMBL12088736 0.76 CHRM2 (0.56) BCHEACHECHRM2SLC6A2SLC6A4
SCHEMBL7636733 0.75 TAAR1 (0.60) CHRM2AOC3HPGDHTTIDO1
SCHEMBL31147801 0.75 TAAR1 (0.60) CHRM2AOC3HPGDHTTIDO1
SCHEMBL13995625 0.74 SIGMAR1 (0.47) BCHECHRM2SLC6A2SLC6A4AOC3
SCHEMBL12477896 0.73 SLC6A2 (0.51) BCHEACHECHRM2SLC6A2SLC6A4
SCHEMBL19398947 0.73 TAAR1 (0.56) CHRM2AOC3HPGDHTTIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 BCHE 4352/4885ACHE 4816/4885CHRM2 4885/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 BCHE 4352/4885ACHE 4816/4885CHRM2 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.